Hertfordshire and West Essex ICB
Prescribing, Policies and Pathways
Prescribing, Policies and Pathways
The last day of operation for Hertfordshire and West Essex ICB was 31 March 2026. The information on this website has not been updated since 31 March 2026. The legacy policies, prescribing recommendations and pathways can be accessed on this website. Find out more
or
| Medicine / Guideline | Indication | RAG rating | Document type | Place |
|---|---|---|---|---|
| Abaloparatide | Osteoporosis after menopause | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Alendronic acid | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Armour thyroid | Hypothyroidism | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Biosimilar insulins (Semglee and Trurapi) | Diabetes | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Bisphosphonates | Osteoporosis | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Blood glucose and ketone meters, test strips and lancets | Diabetes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Blood glucose meters, test strips and lancets | Type 2 diabetes | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Blood glucose test strips and lancets discontinuation letter | Type 2 diabetes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Blood glucose test strips and lancets quantity calculator | Diabetes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Calcium & vitamin D | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Canagliflozin | Chronic kidney disease | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Carbimazole 10mg tablets dose optimisation switch patient letter | Hyperthyroidism | Green | Patient information | Hertfordshire and West Essex ICB |
| Carbimazole 15mg tablets dose optimisation switch patient letter | Hyperthyroidism | Green | Patient information | Hertfordshire and West Essex ICB |
| Continuous Glucose Monitoring - Adults - Initiation Specialist to GP letter | Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Continuous Glucose Monitoring - Dexcom ONE to ONE+ Switch Letter to Patient | Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Continuous Glucose Monitoring - Discontinuation Specialist to GP letter | Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Continuous Glucose Monitoring - FSL2 to FSL2 Plus Sensor Switch Letter to Patient | Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Continuous Glucose Monitoring - FSL3 to FSL3 Plus Sensor Switch Letter to Patient | Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Continuous Glucose Monitoring - Paediatric - Initiation Specialist to GP letter | Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Continuous Glucose Monitoring for Adults: Position Statement | n/a | Position statement | Hertfordshire and West Essex ICB | |
| Continuous Glucose Monitoring for patients with Type1 and Type 2 Diabetes | n/a | Patient information | Hertfordshire and West Essex ICB | |
| Continuous Glucose Monitoring Paediatrics: Position Statement | n/a | Position statement | Hertfordshire and West Essex ICB | |
| Dapagliflozin | Diabetes type 1 | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Dapagliflozin | Chronic kidney disease | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Dapagliflozin patient friendly information resource | n/a | Patient information | Hertfordshire and West Essex ICB | |
| Dapagliflozin Switch Guidance | n/a | Prescribing guideline | Hertfordshire and West Essex ICB | |
| Dapagliflozin switch patient letter | Diabetes | n/a | Prescribing support document | Hertfordshire and West Essex ICB |
| Denosumab | Osteoporosis | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Denosumab 60mg biosimilar: Patient Information | Osteoporosis | Amber initiation | Patient information | Hertfordshire and West Essex ICB |
| Denosumab letter template | Osteoporosis | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Denosumab prescribing support document | Osteoporosis | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Deprescribing in Adults with Type 2 Diabetes | Type 2 diabetes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Diabetes | n/a | Clinical pathways | South and West Hertfordshire | |
| Diabetes - Structured Education for Type 2 | n/a | Patient information | East and North Hertfordshire | |
| Diabetes type 1 | What to do when you are ill | n/a | Patient information | Hertfordshire and West Essex ICB |
| Diabetes type 2 | What to do when you are ill | n/a | Patient information | Hertfordshire and West Essex ICB |
| Diabetes type 2 | Diabetic ketoacidosis (DKA) | n/a | Patient information | Hertfordshire and West Essex ICB |
| Dipeptidyl peptidase-4 inhibitors (Gliptins) | Diabetes type 2 | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Dual GIP with GLP-1 RA or GLP-1 RA with Insulin guidance document | Type 2 Diabetes | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Dual GIP with GLP-1 RA or GLP-1RA comparison document | Type 2 Diabetes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Empagliflozin | Chronic kidney disease | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Exercise Protocol for the Management of CHD (Exercise for Cardiac Conditions) | n/a | Clinical pathways | East and North Hertfordshire | |
| Foot Health for Diabetic Patients | n/a | Patient information | East and North Hertfordshire | |
| Glucophage SR tablets to generic-switch-letter | Diabetes | n/a | Patient information | Hertfordshire and West Essex ICB |
| Guidance for Self-monitoring of Blood Glucose (SMBG) for patients with Diabetes Mellitus | Diabetes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| HRT Hormone Replacement Therapy Guidance | HRT | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Hybrid Closed Loop Systems for Adults: Local Implementation plans | n/a | Position statement | Hertfordshire and West Essex ICB | |
| Hybrid Closed Loop Systems for Children and Young People aged under 19 years | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Hydrocortisone (Alkindi) | Adrenal insufficiency | Double Red | n/a | Hertfordshire and West Essex ICB |
| Hydrocortisone (Plenadren) | Adrenal insufficiency | Double Red | n/a | Hertfordshire and West Essex ICB |
| Ibandronic acid - oral | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Ibandronic acid IV | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Insulin Fiasp | Diabetes type 1 | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Insulin lispro (Lyumjev) | Diabetes type 1 | Double Red | n/a | Hertfordshire and West Essex ICB |
| Insulin Pumps: Position Statement | n/a | Position statement | Hertfordshire and West Essex ICB | |
| Ketone test strip | Diabetic ketoacidosis (DKA) sick day | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Levemir Discontinuation - System Planning Document | Diabetes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Levothyroxine solution to tablets switch patient letter | hypothyroidism | n/a | Patient information | Hertfordshire and West Essex ICB |
| Liothyronine | Hypothyroidism | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
| Liothyronine - Position Statement | Hypothyroidism | Amber protocol | Position statement | Hertfordshire and West Essex ICB |
| Liothyronine – Information for Patients | Hypothyroidism | Amber protocol | Patient information | Hertfordshire and West Essex ICB |
| Liothyronine Review Algorithm | Hypothyroidism | Amber protocol | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Liraglutide | Obesity in people aged 12 to 17 years | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Liraglutide | Overweight and obesity management | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Mecasermin | Growth failure (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Mercaptamine | Corneal cystine deposits (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
| Metformin | Diabetes type 2 | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Metformin oral solution to tablets switch patient letter | Diabetes | n/a | Patient information | Hertfordshire and West Essex ICB |
| Naltrexone–bupropion | Overweight and obesity | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Needles for pre-filled / reusable insulin or GLP-1 receptor agonist pens | Diabetes | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Needles Patient Information Leaflet | Diabetes | n/a | Patient information | Hertfordshire and West Essex ICB |
| NICE NG28 Visual summary on choosing medicines for type 2 diabetes in adults | Type 2 diabetes | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Optimising Prescribing in Diabetes - Quick Reference Guide | Diabetes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Osteoporosis | Osteoporosis | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Paediatric Suspected Diabetes Same Day Referral Pathway - Children and Young People (CYP) 0-18 years | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Paricalcitol | Hyperparathyroidism (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Pen needles switch patient letter | Diabetes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Penicillamine | Tertiary care indication (NHSE) | Amber protocol | n/a | Hertfordshire and West Essex ICB |
| Pre Diabetes | n/a | Patient information | Hertfordshire and West Essex ICB | |
| Prednisolone | All indications - soluble tablet | n/a | Patient information | Hertfordshire and West Essex ICB |
| Prednisolone enteric coated | All indications | Double Red | n/a | Hertfordshire and West Essex ICB |
| Prescribing of GLP1 Receptor Agonists for Weight Loss – Restricted | Weight management | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Qtern | Diabetes type 2 | Double Red | Decision document | Hertfordshire and West Essex ICB |
| Raloxifene | Osteoporosis | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Referral to Consultant-Led Tier 3 Weight Management Services | n/a | Clinical policy | Hertfordshire and West Essex ICB | |
| Reusable Insulin Pen Device Guide | Diabetes | Green | Prescribing support document | Hertfordshire and West Essex ICB |
| Risedronate | Osteoporosis | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Romosozumab | Osteoporosis | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Safety needles letter | Diabetes | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Semaglutide | Overweight and obesity management - adults | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Semaglutide | Overweight and obesity management - young people aged 12 to 17 years | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Semaglutide | Diabetes type 2 | n/a | Patient information | Hertfordshire and West Essex ICB |
| SGLT2 inhibitors | Diabetes type 2 | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Sitagliptin | Diabetes type 2 | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Sitagliptin | Diabetes type 2 | n/a | Primary Care prescribing resource | Hertfordshire and West Essex ICB |
| Somapacitan | Growth disturbance caused by growth hormone deficiency in children | Red | Decision document | Hertfordshire and West Essex ICB |
| Somatrogon (Ngenla) | Growth disturbance caused by growth hormone deficiency in children | Red | Decision document | Hertfordshire and West Essex ICB |
| Somatropin | Treatment of adults with growth hormone deficiency | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
| Somatropin | Treatment of growth failure in children | Amber protocol | Shared care protocol | Hertfordshire and West Essex ICB |
| Strontium | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Teriparatide | Osteoporosis | Red | Prescribing pathway | Hertfordshire and West Essex ICB |
| Testosterone | Menopause | Amber initiation | Prescribing guideline | Hertfordshire and West Essex ICB |
| Testosterone | Menopause | n/a | Patient information | Hertfordshire and West Essex ICB |
| Testosterone gel | Menopause | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Testosterone transdermal gel (Testavan®, Testogel® or Tostran®) | Male primary hypogonadism in patients aged 18 years and over | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Testosterone undecanoate (Nebido®) | Male primary hypogonadism in patients aged 18 years and over | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Tirzepatide | Diabetes type 2 | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Tirzepatide for obesity | Overweight and Obesity | Green | Decision document | Hertfordshire and West Essex ICB |
| Tolvaptan | Kidney disease - autosomal dominant polycystic | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Tolvaptan | Hyponatraemia secondary to SIADH | Red | Decision document | Hertfordshire and West Essex ICB |
| Treatment for diabetic hypoglycaemia (hypos) - Position statement | Diabetes – Hypoglycaemia | n/a | Position statement | South and West Hertfordshire |
| Trientine | Wilsons disease | Red | n/a | Hertfordshire and West Essex ICB |
| Triptorelin as Decapeptyl SR®– Gonadorelin analogue of choice within licensed indications | All licensed indications | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Weight Management | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Zolendronic acid | Osteoporosis | Red | Prescribing guideline | Hertfordshire and West Essex ICB |